Frontlight ResearchEarly access
Taking people in AustriaPhase 4
Steroid timing and blood sugar in adults with ANCA vasculitis
Tests whether splitting steroid doses across the day changes blood sugar in adults with vasculitis.
Key facts
- Who runs it
- Medical University Of Graz
- Where
- Graz, AustriaSee the site
- Registry title
- EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 10 people, planned
- Started
- 25 Sept 2020
- Planned end
- 31 Dec 2024
- Type of study
- Interventional
- Record updated
- 18 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-80 with newly diagnosed ANCA-associated vasculitis or a relapse, who take a high prednisolone dose and will wear a glucose sensor.
- Age
- 18-80 years at the time of biopsy
- Sex
- Men and women
- Disease stage
- New diagnosis of ANCA-associated vasculitis, or a relapse of known ANCA vasculitis
- Earlier treatment
- A prednisolone dose of 1mg/kg body weight at the time of inclusion
Main reasons for not taking part
- Known diabetes mellitus
- Women who can have children and are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception
- Skin changes that prevent placing a glucose sensor
- Taking part in another clinical trial that could affect the results
- Unable to follow study procedures or understand the consent form
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Written agreement to participate in the study after detailed explanation of the study
- Male or female patients
- New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis
- Age: ≥18-80 years at the time of biopsy
- Aprednislon dose of 1mg/kg body weight at the time of inclusion
- Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed
Who cannot take part
- Known diabetes mellitus
- Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results
- Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue)
- Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception
- Current participation in another clinical trial that would affect study results
- Patient's inability to follow study procedures as required
- Inability of the patient to understand the consent form
Where in Austria
- Medical University of GrazGraz, AustriaTaking people
About the trial
What the trial wants to find out
Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
- Plain-language title
- Steroid timing and blood sugar in adults with ANCA vasculitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 November 2024